Friday, April 30, 2010

Product Liability claims for off label marketing

›
After agreeing to pay $520 million to settle civil charges for off-label marketing of its Seroquel antipsychotic, AstraZeneca still faces an...

More on "off label marketing"

›
Here is a link to an editorial in St. Louis Today that argues that off-label marketing should remain illegal.

Thoughts on the "learned intermediary doctrine"

›
In a comment on whether the ban on "off label marketing should be eliminated (available here ), the blog Tort Deform makes the case for...

This Week's Top Stories

›
Go here for the list of last week's most interesting Tort Law stories as selected by the TortsProf Blog. In addition, go here and scro...

DOJ continues to fine pharmaceutical companies for "off label marketing"

›
At the end of last year I predicted that the issue of "off label marketing" would become the "hot" topic in 2010 ( here ...
Friday, April 23, 2010

New York court adds to the confusion re assumption of the risk

›
Long time readers of this blog will remember that I have criticized New York courts on more than one occasion for their sloppy analysis when...

Pharmaceutical company goes after defeated plaintiff

›
Back in 2007, 7-year-old Kristen Spears, who suffered from cerebral palsy, was administered a series of therapeutic Botox shots to relax the...

This Week's Top Stories

›
Go here for the list of last week's most interesting Tort Law stories as selected by the TortsProf Blog. In addition, go here for my o...
Monday, April 19, 2010

FDA considers halting Avandia safety study; taking the drug off the market next?

›
Back in February I reported that an FDA report concluded that diabetes prescription drug Avandia should be withdrawn from the market because...
Friday, April 16, 2010

Further thoughts on sperm case

›
A few days ago, I wrote about Donovan v. Idant Laboratories , in which the court held that genetic defects in sperm from a sperm bank cannot...